Study design
This is a multicenter, randomized, parallel-group clinical trial conducted in China to investigate the impact of electroacupuncture intervention on the incidence of PUR. The study protocol is to prefer the Consolidated Standards of Reporting Trials (CONSORT) guidelines[12] and the Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA)[13], as well as with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)[14]statement The study will commence following ethics approval and registration protocol. Patient screening and inclusion will start in August 2024. It has been registered at Chinese Clinical Trials Registry (ChiCTR2300078039). Figure1 is the study flow chart and Table 1 shows the schedule of enrolment, interventions and assessments.
Table 1. the Schedule of Enrolment, Interventions and Assessments.Interventions and Assessments.
Participants
Recruitment and withdrawal
Patient screening and recruitment will take place at four hospitals in China: the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin Shuige Hospital and Second People's Hospital of Fengrun District, Tangshan City. The target enrollment is set at 660 patients. Obstetricians responsible for identifying eligible patients will be briefed about the study, and these patients will then be given the option to decide whether they want to participate. After signing the informed consent form, patients will be randomly assigned to either the electro-acupuncture group or the sham acupuncture group, with 330 patients allocated to each group. It is important to emphasize that patients have the right to withdraw from the study at any stage.
Inclusion criteria
Patients meeting the following additional inclusion criteria may be included:
1. Primiparous women aged 20 to 45 years with singleton pregnancies planning for vaginal delivery.
2. Delivery at a gestational age of 37 to 42 weeks.
3. Being clearly conscious and cooperative.
4. Signing the informed consent.
Exclusion criteria:
Patients meeting any of the following conditions will be excluded:
1. Termination of pregnancy due to fetal malformation or stillbirth.
2. Severe central nervous system diseases, internal and surgical diseases, mental and psychological diseases, urogenital-related diseases, infectious diseases, and long-term drug treatment.
3. Severe coagulation disorders and a tendency towards spontaneous bleeding.
4. Skin damage at the acupuncture site.
5. Refusal to follow-up.
6. Refusal to sign the informed consent form.
Drop-out and discontinuation criteria:
One of the following conditions occurs during the study, who will be included in the full analysis set in principle, but not in accordance with the per-protocol set for analysis, and acupuncture patients will be included in the safety analysis.
1. Rescue measures are implemented due to postpartum hemorrhage, eclampsia, or other obstetric conditions;
2. Conversion from vaginal delivery to cesarean section
3. Infection is diagnosed during delivery;
4. An indwelling catheter is used and diuretics are administered due to other diseases within 6 hours after delivery;
5. A degree III laceration above the perineal fissure is diagnosed;
6. Due to other postpartum reasons, the number of treatment sessions received by patients is less than 3 times, which affects the analysis and judgment of the results;
7. The researchers can terminate the patients from the study at any stage if any events occur that may affect the safety of patients in the study.
Randomization and blinding
This study will use the network-based clinical trial public management platform (ResMan, http://www.medresman.org.cn/login.aspx) to implement centralized randomization.Randomization will be conducted at each sub-center by block randomization (with a block size of 4). Once patients have signed the informed consent form and completed all necessary baseline assessments, researchers will retrieve the corresponding blind envelope, input the number on the envelope into the ResMan database, and select the corresponding patients' treatment plan. Both patients and researchers will be blinded to the group allocation. However, acupuncturists will be aware of the group allocation for the purposes of acupuncture operation.
After the final acupuncture treatment, all patients will be asked, "Do you believe that acupuncture has penetrated the skin?" The response will be categorized into three options:
- Acupuncture penetrated the skin;
- Acupuncture did not penetrate the skin;
- I don't know.
This will be taken into consideration to evaluate the success of blinding.
Interventions
Each acupuncture treatment modality will involve three sessions, each lasting 30 minutes, administered over two consecutive days (first hour, first day, second day after delivery). The selection of acupuncture points is based on traditional Chinese medicine theory, evidence-based clinical research, and our accumulated clinical experience. The treatment protocol adheres to CONSORT and STRICTA recommendations, providing comprehensive details on the treatment, including the number of needles used, session frequency, and treatment duration. Only licensed acupuncturists holding a master's degree and possessing more than two years of acupuncture experience will conduct the treatment. Prior to the study commencement, all acupuncturists at each sub-center will receive instruction in the theory of postpartum urinary retention and standardized operating procedures.
Electro-acupuncture group
The selected acupoints will include Baihui (GV20), Zhongji (CV3), and Guanyuan (CV4), adhering strictly to the National Acupoint Standard of the People’s Republic of China in 2021 (GB/T 12346-2021). Detailed positioning is illustrated in Table 2 and Figure 2. Patients will be positioned supine during the procedure. Adhesive pads will be applied to the skin over the acupoints, followed by the insertion of single-use acupuncture needles (0.25 * 40 mm, Hwato, Suzhou, China) through the adhesive pads.
The sequence and technique of acupuncture are as follows: initially, acupuncture at Baihui (GV20) will be performed with a depth of 10-15mm and an angle parallel to the scalp. Subsequently, a small amplitude and high-frequency twisting method will be applied, with the needle twirling in the range of 90°-180° at a frequency of 100 to 120 times per minute for 1 minute. Following this, Zhongji (CV3) and Guanyuan (CV4) will be obliquely punctured at a depth of 10-20mm and at a 45° angle to the abdomen. The same small amplitude and high-frequency twisting method will be employed for 1 minute. Acupuncturists will manually stimulate the needles to achieve de qi, and then paired electrodes from an electroacupuncture (EA) apparatus (SDZ-ⅡB, Suzhou Medical Appliance, Suzhou, Jiangsu, China) will be attached to the needle handles at CV3 and CV4. The wave will be set continuously at 2 Hz, with the intensity adjusted to the maximum tolerated by the patients. The needles will be retained for 30 minutes. The specific operation and electrode connection are depicted in Figure 2.
Table2. Locations and needling methods of acupoints for electro-acupuncture group
Acupoint
|
Location
|
Needling method
|
Baihui (GV20)
|
On the head, 5 inches above the center of the front hairline.
|
depth of 10-15mm and an angle parallel to the scalp, then adopt the method of small amplitude and high frequency twisting(the range of twirling of the needle was 90°- 180°, and the frequency was 100 to 120 times a minute) for 1 min.
|
Zhongji (CV3)
|
In the lower abdomen, 4 cun below the umbilicus, on the anterior median line.
|
obliquely acupunctured 10-20mm and at a 45° angle to the abdomen.
|
Guanyuan (CV4)
|
In the lower abdomen, 3 cun below the umbilicus, on the anterior median line.
|
obliquely acupunctured 10-20mm and at a 45° angle to the abdomen.
|
Sham acupuncture group
Patients in the sham acupuncture group will undergo non-insertive acupuncture treatment following the same procedure as the electro-acupuncture group. However, the treatment will be applied to non-acupoints (sham-Baihui, sham-Zhongji, sham-Guanyuan) using sham needles with a blunt tip (0.25 × 40 mm, Hwato, Suzhou, China). The sham needles will not penetrate the skin, and the procedure will not aim to elicit the "De Qi" sensation. An EA apparatus will be attached to the needle handles at sham-Zhongji and sham-Guanyuan, but no electricity output will be applied. The needles will be retained for 30 minutes. Specific positioning and operation details are outlined in Table 3 and Figure 2.
Table3. Locations and needling methods of non-acupoints for Sham group
Acupoint
|
Location
|
Needling method
|
Sham-Baihui
|
2 cun lateral from GV20
|
Sham needles will not penetrate the skin
|
Sham-Zhongji
|
6 cun lateral from CV4(left)
|
Sham needles will not penetrate the skin
|
Sham-Guanyuan
|
6 cun lateral from CV4(right)
|
Sham needles will not penetrate the skin
|
Outcome measurements
At the baseline, clinical and sociodemographic data will be collected from all patients, encompassing:
1.Basic Information:
- Age;
- Gestational age at delivery;
- Height;
- Weight (Predelivery);
- Body Mass Index (Predelivery);
- Conception mode.
2. Management of the Delivery Process:
- Duration of labor;
- Use of epidural anesthesia;
- Incidence of episiotomy and perineal lacerations;
- Instances of vacuum-assisted and instrumental delivery;
- Process of placental delivery;
- Administration of uterine contractile drugs.
3. Newborn Condition:
- Weight;
- Length;
- Apgar score.
Primary outcome
The primary outcome is the PUR incidence.
The PVR of the bladder will be measured using an Ultrasonic Bladder Scanner (BVI-9400 BladderScan®, Verathon Medical Europe, Ijsselstein, The Netherlands) at specific time points: the first urination after delivery, 6 hours after delivery, the initial urination on the first day, and the second day following acupuncture. The recorded PVR of the bladder and whether catheterization was required will be documented. The specific measurement times are illustrated in Figure 3.
Secondary outcome
The time of first urination, the amount of urination and the feeling of unobstructed urination.
1.Recording Time from Delivery Completion to First Urination:
The elapsed time from the conclusion of delivery to the initiation of the first urination will be recorded, measured in minutes ("min").
2.Recording Volume of First Post-Delivery Urination:
After urination in a urinal, the volume of urine will be measured using a cup, expressed in milliliters ("mL").
3.Assessment of Unobstructed Feeling During First Urination:
The unobstructed sensation during the initial urination will be evaluated using the Traditional Chinese Medicine Syndrome Quantification Scale, where:
- 0 points: Unable to urinate;
- 2 points: Dribbling out urine, with a sense of difficulty;
- 4 points: Urination is acceptable, with a residual feeling;
- 6 points: Very smooth, without any residual sensation.
Effective rate of urination
The classification of the first urination volume is as follows:
- A volume greater than 500 ml is considered significant;
- A volume ranging from 100 to 500 ml is deemed effective;
- A volume less than 100 ml is categorized as invalid.
The effective rate of urination is calculated using the formula: Effective rate of urination=(number of significant cases + number of effective cases)/total cases × 100%.
Postpartum uterine contraction pain
The Visual Analogue Scale (VAS) will be employed to assess postpartum uterine contraction pain. The visual scale spans 10 centimeters, ranging from 0 to 10, where "0" represents a painless state, and "10" signifies the most unbearable pain. Scores will be assigned at specific time points, including six hours after delivery, two hours after acupuncture on the first day, and two hours after acupuncture on the second day.
Cumulative amount of 24 hours postpartum bleeding
The volume of vaginal bleeding within the first 24 hours after delivery will be documented using postpartum measuring pads. These pads will be changed regularly every 2-4 hours, and upon replacement, they will be weighed and measured, with the unit of measurement being milliliters ("mL").
Postpartum depression and anxiety
The Edinburgh Postpartum Depression Scale (EPDS) will be employed to assess depressive symptoms. The scale comprises 10 items, which will be administered after the final acupuncture session and again 6-8 weeks after delivery. Each item is graded on a four-point scale (0 to 3 points). A cumulative total score of ≥13 points indicates a diagnosis of postpartum depression.
Safety assessment
Common adverse reactions associated with acupuncture include incidents such as broken needles, localized hematoma, bleeding, infection, and localized severe sharp pain. Post-delivery, common adverse reactions encompass late postpartum hemorrhage, postpartum infection, and constipation. Any adverse events (AEs) occurring during the study period will be thoroughly assessed, treated, and documented in the case report form (CRF).
Follow-up
Follow-up 1—6-8 weeks after delivery
Patients will undergo follow-up through outpatient visits. Urination sensations will be assessed using the Traditional Chinese Medicine Syndrome Quantification Scale, where:
- 0 points: Unable to urinate;
- 2 points: Dribbling out urine, with a sense of difficulty;
- 4 points: Urination is acceptable, with a residual feeling;
- 6 points: Very smooth, without any residual sensation.
Follow-up 2—One year after delivery
Patients will be followed up via telephone. The assessment will include monitoring symptoms related to urination, defecation, and pelvic organ prolapse. Additionally, the Pelvic Floor Dysfunction Questionnaire (PFDI-20) will be administered.
Data management and monitoring
CRFs will be developed to record and store individual patient data. To streamline data management and process monitoring, an electronic CRF based on the ResMan network system will be employed for data management. After researchers input the data and address any inquiries to guarantee accuracy, database locking will be conducted by data administrators. Both hardcopy files and electronic documents will be archived for a minimum of 5 years post-publication. In the event that readers or reviewers have queries, they can contact the corresponding author to access the original data. Moreover, an independent Data and Safety Monitoring Board (DSMB in Table4) will be established to review and interpret the data generated during the study. The primary objective is to safeguard patient safety and maintain data integrity throughout the research. The DSMB will offer recommendations on research design, data quality, and analysis, thereby ensuring the protection of subjects involved in the study.
Table4. Data and Safety Monitoring Board (DSMB)
Member name
|
Affiliation
|
Roles and responsibilities
|
Linling Wu
|
First Teaching Hospital of Tianjin University of TCM
|
- Review the protocol with respect to ethical and safety standards.
- Review the progress of the trial.
|
Ning Xue
|
First Teaching Hospital of Tianjin University of TCM
|
- Monitor the safety of the trials.
- Review and interpret the data generated from the study.
|
Zhimei Zhao
|
First Teaching Hospital of Tianjin University of TCM
|
- Adjudicate adverse events.
|
Quality control
To ensure the trials' quality, standardized training will be provided to all acupuncturists, obstetricians, evaluators, and statisticians before the official launch of the clinical trial. The training will encompass research goals and content, patient recruitment, treatment procedures, patient communication skills, and outcome evaluation, aiming to maintain consistency across various patients and researchers. This approach ensures the feasibility and safety of the clinical research. Throughout the clinical trial, independent monitors will regularly visit each center to verify strict adherence to the research plan. They will also scrutinize the original data to ensure the CRFs are accurate, complete, and correct.
Sample size
This study adopts a superiority design. Based on the research findings, the incidence of overt Postpartum Urinary Retention in the intervention group is projected at 4.0%, while in the control group, it is estimated to be 9.0% [4]. Assuming a 1:1 ratio between the intervention and control groups, and utilizing a superiority test with a significance level (α) of 0.05, a power (1-β) of 80%, and accounting for a potential dropout rate of 10%, the study is planned to enroll 660 patients, evenly distributed with 330 in each group. The calculation formula is as follows:
Statistical analysis
Demographic characteristics, general situations, and baseline conditions of the two groups will be compared and analyzed. For measurement data, an independent samples t-test or Wilcoxon rank-sum test will be employed, while χ2 test or Fisher test will be used for categorical data.
The incidence of PUR will be accurately assessed using Fisher's exact test, and the relative risk (RR) along with the corresponding 95% confidence interval will be calculated. For other ordinal data, the Wilcoxon rank-sum test will be applied, while clinical counting data will undergo testing through the χ2 test. Postpartum depression and anxiety will be compared using Fisher's exact test, and the RR along with the corresponding 95% confidence interval will be computed. Subject blinding effectiveness will be analyzed using the Bang Blinding Index and James Blinding Index. All statistical tests will be two-sided, and a P value less than 0.05 will be considered statistically significant for the tested differences.
For exploratory subgroup analysis, participants will be stratified into different subgroups based on age (< 40 years, ≥ 40 years), BMI (< 25kg/m2, ≥ 25kg/m2), duration of labor (< 700min, ≥ 700min), epidural anesthesia (with or without), vaginal midwifery techniques (forceps midwifery, fetal head attraction midwifery, fetal head rotation, perineotomy), gestational age (> 280 days, ≤ 280 days), and newborn birth weight (< 4000g, ≥ 4000g). The incidence difference between the two groups will be compared within each subgroup using the same statistical methods as mentioned above. Due to the exploratory nature of this analysis, no adjustments for multiple testing will be made at this stage.
GraphPad Prism 8 will be used for all statistical analysis.